Moderna says it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza’s facility; The Chan Zuckerberg Initiative is building a virtual cell to predict how every cell in the human body will behave.
Five things for pharma marketers to know: Tuesday September 19, 2023
BioNTech starting Phase 1/2 trials for mRNA-based mpox vaccine following Moderna’s lead; Novo Nordisk hires PCI Pharma Services to handle assembly and packaging of Wegovy; LEO Pharma to acquire Timber Pharmaceuticals in $36 million deal.
Five things for pharma marketers to know: Monday, September 18, 2023
Alnylam Pharmaceuticals’ stock price fell after FDA advisers weigh the risks and benefits of the company’s ATTR-CM treatment; Digital health startup Akili cuts staff by 40%, abandons its prescription model; Florida surgeon general advises residents under 65 not to get new COVID boosters.
As more patients email doctors, health systems start charging fees
Spurred by the sharp rise in email messaging during the covid pandemic, a growing number of health systems around the country have started charging patients when physicians and other clinicians send replies to their messages.
Five things for pharma marketers to know: Thursday, September 14, 2023
Regeneron deal marks the first time the Biden administration uses its leverage to challenge drugmakers’ list prices; Rocket Pharmaceuticals’ stock surges after aligning with FDA regarding global Phase 2 trial; Former J&J CEO Alex Gorsky joins Neurotech board.
DPE 2023 panel recap: Cancer survivors call on healthcare marketers to ‘humanize healthcare’
FDA adcomm says ingredient in oral decongestants doesn’t work; A medical researcher asks court to throw out Johnson & Johnson lawsuit; 2seventy Bio cuts 40% of staff, including CEO.